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recBACKGROUND Vorapaxar, a novel antiplatelet therapy, reduces thrombotic events in patients with a history of
myocardial infarction (MI) or peripheral artery disease (PAD); however, because of an increased risk of intracranial
hemorrhage, it is contraindicated in patients with a history of stroke.
OBJECTIVES The aim of this study was to investigate the incidence of new ischemic stroke and subsequent death or
intracerebral hemorrhage in patients with MI or PAD and no cerebrovascular disease (CVD) treated with vorapaxar.
METHODS The TRA 2P-TIMI 50 (Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in
Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a randomized, double-blind, placebo-
controlled trial of vorapaxar 2.5 mg daily in 26,449 patients with atherosclerosis, stratiﬁed by qualifying disease (MI,
PAD, or CVD). A total of 20,170 patients with MI/PAD, but no CVD, were enrolled.
RESULTS In patients with MI/PAD and no prior stroke or transient ischemic attack, vorapaxar reduced ﬁrst ischemic
stroke (hazard ratio [HR]: 0.57, 95% conﬁdence interval [CI]: 0.43 to 0.75; p < 0.001). The risk of hemorrhagic con-
version after stroke (HR: 1.19, 95% CI: 0.49 to 2.91; p ¼ 0.70) or death (HR: 1.09, 95% CI: 0.57 to 2.07; p ¼ 0.79) during
follow-up was not signiﬁcantly increased with vorapaxar in patients who had a new ischemic stroke (n ¼ 204). Although
hemorrhagic stroke was increased (HR: 2.79, 95% CI: 1.00 to 7.73; p ¼ 0.049), overall stroke was signiﬁcantly reduced
(HR: 0.67, 95% CI: 0.52 to 0.87; p ¼ 0.002).
CONCLUSIONS Vorapaxar reduces ischemic stroke in patients with MI or PAD and no known CVD. There does not
appear to be a signiﬁcant increase in the risk of hemorrhagic conversion or death in patients who experienced a ﬁrst
ischemic stroke on vorapaxar. Although primary hemorrhagic stroke is increased, vorapaxar reduces the total incidence of
stroke. (Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in
Patients With Atherosclerosis [TRA 2P-TIMI 50]; NCT00526474) (J Am Coll Cardiol 2014;64:2318–26) © 2014 by the
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
CVD = cerebrovascular disease
DAPT = dual antiplatelet
therapy
HR = hazard ratio
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2319V orapaxar is a novel thrombin receptor antag-onist that has potent antiplatelet effectsand reduces atherothrombotic events in
patients with stable atherosclerotic vascular disease
(1). This beneﬁt is balanced against an increased
risk of bleeding, including a risk of intracranial hem-
orrhage that is highest in patients with a prior stroke
or transient ischemic attack (TIA) (1,2). A similarSEE PAGE 2327
MI = myocardial infarction
MRS = modiﬁed Rankin Scale
PAD = peripheral
artery disease
TIA = transient ischemic attackheterogeneous response by symptomatic vascular
territory was observed with other potent antiplatelet
agents and is reﬂected in current guidelines for
patients with cerebrovascular disease (CVD) (3–8).
Vorapaxar was recommended for approval for clinical
use in the United States in patients with prior
myocardial infarction (MI) or peripheral artery dis-
ease (PAD), but no prior stroke or TIA (9). Because
this population is at a heightened risk of a ﬁrst
ischemic stroke, and any such event occurring on vor-
apaxar could expose a patient to an increased risk
of harm, understanding the incidence of stroke and
subsequent outcomes with vorapaxar in this popula-
tion will be important to clinicians (5,10,11).
The TRA 2P-TIMI 50 (Trial to Assess the Effects of
Vorapaxar in Preventing Heart Attack and Stroke in
Patients With Atherosclerosis-Thrombolysis In
Myocardial Infarction 50) studied vorapaxar for sec-
ondary prevention of atherothrombosis in patients
with stable atherosclerosis, including prior MI,
symptomatic PAD, or ischemic stroke (1,12). We pre-
viously characterized the risks of intracranial hem-
orrhage and total stroke in the overall population and
in the key subgroup of patients who qualiﬁed for the
trial with prior MI, including those with a concomi-
tant history of CVD (13).
The present report is, therefore, focused on the key
clinical issue of the incidence of ﬁrst stroke and
associated outcomes in patients with history of MI or
PAD, and no history of CVD, who are treated with
vorapaxar in addition to standard antiplateletfor Merck & Co. Dr. Wiviott has received research grants from Merck & Co., A
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Manuscript received April 8, 2014; revised manuscript received June 23, 201therapy. Because antiplatelet therapy has
directionally opposite effects on ischemic
stroke versus primary hemorrhagic stroke, we
now discriminate between the occurrences of
these forms of stroke and provide an analysis
of their functional severity.
METHODS
STUDY POPULATION AND PROCEDURES. TRA
2P-TIMI 50 (Trial to Assess the Effects of
Vorapaxar in Preventing Heart Attack and
Stroke in Patients With Atherosclerosis) was
a multinational, randomized, double-blind, placebo-
controlled trial among 26,449 subjects with stable
atherosclerotic vascular disease manifest by prior
MI, PAD, or ischemic stroke (12). Details of the trial
design were previously reported (1,12). Participants
entering the trial with a prior MI or PAD and without
a history of prior CVD, deﬁned as prior stroke or TIA,
are the basis for the present study. Patients with MI
qualiﬁed on the basis of a history of spontaneous MI
occurring 2 weeks to 12 months before randomiza-
tion (1). Patients with PAD qualiﬁed by a history of
intermittent claudication in conjunction with an
ankle-brachial index <0.85 or previous revasculari-
zation for limb ischemia. Randomization was strati-
ﬁed according to the qualifying diagnosis (12).
Patients were ineligible if they had a planned
revascularization, a history of a bleeding diathesis,
were receiving vitamin K antagonist therapy, or had
a history of intracranial bleeding (12).
Eligible patients were randomized in a 1:1 fashion to
receive vorapaxar 2.5 mg daily or matching placebo.
After the data safety monitoring board’s recommen-
dation, the protocol was amended to discontinue the
study drug in patients with a history of stroke or
at the time of an occurrence of a new stroke during the
trial (1,12). Randomization was stratiﬁed both by
qualifying disease state and by the pre-randomization
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TABLE 1 Baseline Characteristics (Randomized Treatment Allocation)
Vorapaxar
(n ¼ 10,080)
Placebo
(n ¼ 10,090) p Value
Demographics
Age 60 (52–67) 60 (52–67) 0.90
Female 2,204 (22) 2,165 (21) 0.48
White race 8,939 (89) 8,924 (88) 0.54
Weight <60 kg 597 (6) 580 (6) 0.61
Clinical characteristics
Diabetes mellitus 2,385 (24) 2,377 (24) 0.86
Hypertension 6,520 (65) 6,564 (65) 0.57
Hyperlipidemia 8,554 (85) 8,573 (85) 0.85
Current smoker 2,143 (21) 2,214 (22) 0.24
Any coronary artery disease 9,341 (93) 9,377 (93) 0.44
Peripheral artery disease 2,313 (23) 2,364 (23) 0.42
CrCl at baseline <60 ml/min 1,186 (12) 1,131 (11) 0.21
Carotid revascularization 191 (2) 169 (2) 0.24
Coronary revascularization 7,953 (79) 7,954 (79) 0.91
Peripheral arterial revascularization 1,171 (12) 1,199 (12) 0.56
Baseline medical therapy
No antiplatelet therapy 77 (1) 102 (1) 0.061
Aspirin 9,746 (97) 9,756 (97) 0.99
Thienopyridine 7,177 (71) 7,215 (72) 0.63
Aspirin and thienopyridine therapy 6,920 (69) 6,983 (69) 0.39
ACE inhibitor or ARB 7,584 (75) 7,713 (76) 0.046
Values are median (interquartile range) or n (%).
ACE ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker;
CrCl ¼ creatinine clearance.
CENTRAL ILLUSTRATION Thrombin Activation of PAR-1 and Ischemic Stroke
Bonaca, M.P. et al. J Am Coll Cardiol. 2014; 64(22):2318–26.
Protease-activated receptor 1 (PAR-1) is expressed on platelets, endothelial and vascular smooth muscle cells and is activated by thrombin.
Vorapaxar is a PAR-1 antagonist, which blocks thrombin mediated platelet activation and reduces ischemic stroke.
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2320ENDPOINTS. The primary efﬁcacy and safety deﬁni-
tions, as well as the main trial results, were previ-
ously described (1). Stroke was a pre-speciﬁed
component of the overall trial primary endpoint.
A stroke endpoint was deﬁned as the new onset of
focal neurological symptoms lasting more than 24 h or
evidence of new infarct on brain imaging, even if
symptoms were <24 h in duration (12). Stroke
events were further classiﬁed as ischemic or pri-
mary hemorrhagic. Ischemic strokes associated with
hemorrhagic conversion were also identiﬁed. Non-
hemorrhagic infarction with hemorrhagic conversion
was deﬁned as evidence of cerebral infarction, with
blood felt to represent hemorrhagic conversion, and
not a primary hemorrhage, on the basis of location and
imaging characteristics. Microhemorrhage evident
on magnetic resonance imaging, whether in the cortex
or deep brain structures, was not considered to meet
the deﬁnition of hemorrhagic conversion. All poten-
tial stroke events were adjudicated by a clinical events
committee comprised of neurology specialists blin-
ded to treatment allocation (12).
CLINICAL ASSESSMENT. Site investigators were
trained in the assessment of disability after stroke us-
ing the modiﬁed Rankin Scale (MRS). Investigators
were instructed to complete an assessment at baseline,
FIGURE 1 Kaplan-Meier Curves for Any Stroke During Follow-Up by
Treatment Allocation
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Stroke during follow-up with vorapaxar versus placebo is shown. Stroke events include
ischemic stroke, ischemic stroke with hemorrhagic conversion, and hemorrhagic stroke.
Outcomes out to 1,080 days (3 years) are shown. CI ¼ conﬁdence interval;
HR ¼ hazard ratio.
FIGURE 2 Kaplan-Meier Curves for Ischemic Stroke During Follow-Up by
Treatment Allocation
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2321at stroke presentation, at discharge from stroke hos-
pitalization, and for the remainder of follow-up. Scores
on the MRS increase with greater disability and range
from 0 (no symptoms) to a maximum of 6 (death), with
a score of 3 indicating moderate disability (14).
STATISTICAL METHODS. Baseline characteristics were
compared using the chi-square test for categorical
variables and the Wilcoxon rank sum test for contin-
uous variables. The efﬁcacy analyses were performed
using a Cox proportional hazards model, with the
investigational treatment allocation, qualifying
atherosclerosis (MI or PAD), and planned use of a
thienopyridine as covariates. The Kaplan-Meier
method was used to calculate cumulative event
rates at 3 years. Efﬁcacy data were analyzed on an
intention-to-treat basis. Safety analyses were per-
formed among patients who received 1 or more doses
of study drug, and included events through 60 days
after premature cessation of study therapy, or 30 days
after a ﬁnal visit at the conclusion of the trial.
Outcomes of interest for this analysis after a ﬁrst
ischemic stroke were death and hemorrhagic con-
version. Analyses were performed using Stata version
12.1 (Stata Corp., College Station, Texas).
RESULTS
BASELINE CHARACTERISTICS. A total of 20,170
patients qualiﬁed for the trial with MI or PAD and had
no history of CVD (Online Figure 1). Median follow-
up in this cohort was 31 months, representing over
52,000 patient-years of observation. Their baseline
characteristics are shown in Table 1. Background
treatment included aspirin in 97%, thienopyridine in
71%, and dual antiplatelet therapy (DAPT) in 69%.
Experimental treatment allocation was well balanced
(Table 1). Therewas frequent use of statin therapy (93%
in those on vorapaxar and 94% in those on placebo)
and angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker therapy (76% overall).
VORAPAXAR AND TOTAL STROKE (ISCHEMIC AND
HEMORRHAGIC). During follow-up, there were 243
new strokes occurring at a median of 507 days
following randomization. Median follow-up was 358
days after a ﬁrst stroke occurring during participation
in the trial. The majority of new strokes were
ischemic strokes without hemorrhagic conversion
(n ¼ 187). Ischemic stroke with hemorrhagic conver-
sion occurred in 20 patients, primary hemorrhagic
stroke in 19 patients, and nonclassiﬁed stroke in 23
patients. Compared with placebo, vorapaxar led to a
signiﬁcant reduction in new stroke in patients with
MI or PAD and no prior stroke or TIA (1.20% vs. 1.65%,hazard ratio [HR]: 0.67, 95% conﬁdence interval [CI]:
0.52 to 0.87; p ¼ 0.002) (Figure 1).
ISCHEMIC STROKE. Vorapaxar reduced ischemic
stroke (74 vs. 130, 0.88% vs. 1.47%, HR: 0.57, 95% CI:
TABLE 2 Efﬁcacy and Bleeding Endpoints
Endpoint
Vorapaxar
(n ¼ 10,080)
Placebo
(n ¼ 10,090) HR (95% CI) p Value
Overall efﬁcacy
CVD/MI/stroke 688 (7.9) 851 (9.5) 0.80 (0.73–0.89) <0.001
CVD/MI/stroke/urgent coronary
revascularization
896 (10.1) 1,073 (11.8) 0.83 (0.76–0.90) <0.001
Stroke endpoints*
Any stroke 98 (1.2) 145 (1.6) 0.67 (0.52–0.87) 0.002
All ischemic stroke 74 (0.9) 130 (1.5) 0.57 (0.43–0.75) <0.001
Ischemic stroke without
hemorrhagic conversion
69 (0.8) 118 (1.3) 0.58 (0.43–0.78) <0.001
Ischemic stroke with
hemorrhagic conversion
8 (0.1) 12 (0.1) 0.67 (0.27–1.63) 0.38
Primary hemorrhagic stroke 14 (0.2) 5 (0.1) 2.79 (1.00–7.74) 0.049
Transient ischemic attack 48 (0.5) 55 (0.7) 0.88 (0.59–1.29) 0.50
Bleeding
GUSTO moderate/severe bleed† 312 (3.8) 202 (2.5) 1.57 (1.32–1.88) <0.001
GUSTO severe bleed† 105 (1.3) 87 (1.1) 1.22 (0.92–1.62) 0.16
Fatal bleed 17 (0.3) 14 (0.2) 1.23 (0.60–2.49) 0.57
Values are n (%) except as indicated. *Any stroke includes 23 strokes of unknown subtype. †Includes fatal
bleeding.
CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; GUSTO ¼ Global Utilization Of Streptokinase and tPA
for Occluded arteries; HR ¼ hazard ratio; MI ¼ myocardial infarction.
FIGURE 3 First Strokes Occurring During Follow-Up by
Stroke Type and Treatment Allocation
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23220.43 to 0.75; p < 0.001) (Figure 2, Table 2), including
ischemic stroke without hemorrhagic conversion
(0.83% vs. 1.33%, HR: 0.58, 95% CI: 0.43 to 0.78;
p < 0.001), with a consistent trend for ischemic stroke
with hemorrhagic conversion (0.10% vs. 0.14%, HR:
0.67, 95% CI: 0.27 to 1.63; p ¼ 0.38) (Figure 3, Table 2).
New transient ischemia was numerically lower in
patients randomized to vorapaxar compared with
placebo (0.53% vs. 0.65%, HR: 0.88; 95% CI: 0.59 to
0.1.29; p ¼ 0.50) (Table 2).
These ﬁndings with respect to new ischemic
stroke were similar among patients who entered the
trial on the basis of MI or PAD (Table 3). In particular,
among patients who qualiﬁed with prior MI, vor-
apaxar reduced the risk of any stroke by 38% and of
ischemic stroke by 49% (Table 3). In patients
enrolled with MI who we previously identiﬁed as at
particularly low risk for bleeding complications
(age <75 years, weight $60 kg, no history of stroke or
TIA; n ¼ 14,909) (10), vorapaxar reduced the occur-
rence of any stroke by 40% and ischemic stroke by
53% (Online Table 1).
OUTCOMES AFTER ISCHEMIC STROKE. In those
patients who experienced a ﬁrst ischemic stroke
during the trial, there was no signiﬁcant increase in
the hazard of hemorrhagic conversion with vorapaxar
compared with placebo (8 of 66 with vorapaxar vs.
12 of 118 with placebo, HR: 1.19, 95% CI: 0.49 to 2.91;
p ¼ 0.70). Moreover, there was no statistically sig-
niﬁcant interaction between planned thienopyridinetherapy and the effect of vorapaxar on the develop-
ment of ischemic stroke with hemorrhagic conversion
(p for interaction ¼ 0.56). In addition, there was no
detectable increase in the hazard of death during
follow-up after a ﬁrst ischemic stroke with vorapaxar
compared with placebo (HR: 1.09, 95% CI: 0.57 to
2.07; p ¼ 0.79) (Figure 4).
At the time of a ﬁrst ischemic stroke, 72% (53 of 74)
of patients randomized to vorapaxar and 70% (91 of
130) of patients randomized to placebo were on study
treatment. When restricting the analysis to those
patients taking study treatment at the time of their
ﬁrst ischemic stroke, there was no increase in subse-
quent hemorrhagic conversion with vorapaxar com-
pared with placebo, whether or not the study drug
was stopped within 30 days after the stroke (3 of 20
with vorapaxar vs. 5 of 39 on placebo) or continued
for 30 days or longer (3 of 33 with vorapaxar vs. 3 of 52
on placebo).
HEMORRHAGIC STROKE. When considering all
patients with MI or PAD and no prior stroke or TIA,
the rate of ischemic stroke with hemorrhagic con-
version was similar with vorapaxar compared with
placebo (0.10% with vorapaxar vs. 0.14% with
placebo, HR: 0.67, 95% CI: 0.27 to 1.63; p ¼ 0.38)
(Table 2, Figure 3). Primary hemorrhagic stroke was
increased with vorapaxar (0.17% vs. 0.06%, HR: 2.79;
95% CI: 1.00 to 7.74; p ¼ 0.049) (Table 2, Figure 3).
Rates of fatal bleeding of any kind (0.3% vs. 0.2%;
p ¼ 0.57) were similar with vorapaxar compared with
placebo (Table 2).
TABLE 3 Vorapaxar Compared With Placebo for Stroke by Qualifying Disease State
Endpoint
MI
(n ¼ 16,897)
PAD
(n ¼ 3,273) p Interaction
Any stroke 0.62 (0.45–0.85) 0.80 (0.51–1.25) 0.35
All ischemic stroke 0.51 (0.36–0.72) 0.71 (0.44–1.14) 0.28
Ischemic stroke without
hemorrhagic conversion
0.51 (0.35–0.74) 0.76 (0.46–1.25) 0.21
Ischemic stroke with
hemorrhagic conversion
0.75 (0.26–2.16) 0.51 (0.093–2.76) 0.70
Values are HR (95% CI).
HR ¼ hazard ratio; PAD ¼ peripheral artery disease; other abbreviations in Table 2.
FIGURE 4 Kaplan-Meier Curves for Death Occurring After Ischemic Stroke
by Treatment Allocation
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2323MRS AFTER STROKE WITH VORAPAXAR. In patients
who experienced an ischemic stroke during trial
follow-up, there was no difference in the mean
MRS after stroke (90 days or last observation carried
forward) with vorapaxar versus placebo (2.7 vs. 2.3;
p ¼ 0.21). The overall reduction in ischemic stroke
was similar across all MRS categories (Figure 5A), and
was consistent for ischemic stroke with and without
hemorrhagic conversion (Online Figures 2 and 3). The
hazard of a moderate-to-severely disabling ischemic
stroke of any kind was reduced with vorapaxar, both
for nonfatal events (MRS 3 to 5, HR: 0.51 95% CI: 0.30
to 0.87; p ¼ 0.013) and for all events, including fatal
strokes (MRS 3 to 6, HR: 0.55 95% CI: 0.35 to 0.87;
p ¼ 0.011) (Online Figure 4). Hemorrhagic stroke was
increased with vorapaxar across MRS, including those
that were fatal (score of 6) (Online Figure 5).
When evaluating all strokes (ischemic and hemor-
rhagic), vorapaxar reduced stroke across MRS cate-
gories, with the exception of a greater number of fatal
strokes (MRS 6) with vorapaxar (20 vs. 15) (Figure 5B).
The hazard of a moderately to severely disabling
nonfatal stroke was reduced with vorapaxar (MRS 3
to 5, HR: 0.51 95% CI: 0.30 to 0.87; p ¼ 0.013),
with a consistent trend when including fatal events
(MRS 3 to 6, HR: 0.73 95% CI: 0.50 to 1.08; p ¼ 0.11)
(Online Figure 5).
INFLUENCE OF BACKGROUND THIENOPYRIDINE
THERAPY. The majority of patients receiving a
thienopyridine were also administered aspirin as
DAPT (Table 1). The reduction in a new stroke of any
kind with vorapaxar compared with placebo was
similar in both patients planned for thienopyridine
therapy (n ¼ 13,452, HR: 0.65, 95% CI: 0.46 to 0.93;
p ¼ 0.018), as well as those not planned for thieno-
pyridine therapy (n ¼ 6,718, HR: 0.70, 95% CI: 0.48 to
1.01; p ¼ 0.022; p for interaction ¼ 0.79) (Figure 6).
Findings were similar for new ischemic stroke (plan-
ned thienopyridine therapy HR: 0.54, 95% CI: 0.37 to
0.80; p ¼ 0.002 vs. no planned thienopyridine
therapy HR: 0.60, 95% CI: 0.39 to 0.91; p ¼ 0.016;
p for interaction ¼ 0.75) (Figure 6). Vorapaxar
was associated with increased rates of hemorrhagic
stroke, regardless of background thienopyridine
(Online Figure 4).
DISCUSSION
Vorapaxar signiﬁcantly reduced the risk of stroke in
patients with a history of MI or PAD and no prior
history of stroke or TIA, the patient group approved
for use by the U.S. Food and Drug Administration
(Central Illustration). This beneﬁt with vorapaxarwas mediated through a signiﬁcant reduction in
ischemic stroke, which represented the majority of
new strokes occurring in this cohort (84%). Vor-
apaxar increased the risk of primary hemorrhagic
stroke; however, due to the infrequency of this
event relative to ischemic stroke, the overall inci-
dence of stroke was reduced. Importantly, in
patients who experienced a ﬁrst ischemic stroke
while taking vorapaxar, there was no signiﬁcant
increase in the risk of hemorrhagic conversion or
death during follow-up. The reduction in ischemic
stroke was consistent across MRS, including
severely disabling and fatal events.
ANTIPLATELET THERAPY AND STROKE. New treat-
ments that prevent stroke are needed (15). Stroke is
the leading cause of long-term disability in the
United States, with about a quarter of patients who
FIGURE 5 MRS After First Stroke of Any Kind and Ischemic Stroke by Treatment Allocation
Rankin Score for First Ischemic Stroke*A B
C D
27
30
14
25
8
6
4
20
14
29
22
20
17
6
15
14
20
7
54
8
11
29
19
19
15
12%
9% 4% 12% 15% 15% 23%
22% 4% 7% 15% 9% 27% 15%
11% 4% 12% 14% 16% 21% 22%22%
6% 7% 16% 10% 29% 20%
5
11
Rankin 6 Rankin 5 Rankin 4
Placebo
160
140
120
Pa
tie
nt
s (
N)
Pa
tie
nt
s (
N)100
80
60
40
20
0
Vorapaxar
Patients (%) Patients (%)
Placebo
Vorapaxar
N=125
N=69
N=125
0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100%
Placebo
Vorapaxar
N=91
N=139
*Ischemic stroke with and without hemorrhagic conversion
*Ischemic stroke with and without hemorrhagic conversion
*Ischemic or hemorrhagic stroke
*Ischemic or hemorrhagic stroke
N=69
Placebo Vorapaxar
N=139 N=91
Rankin 3 Rankin 2 Rankin 1 Rankin 0
Rankin Score for First Ischemic Stroke*
Rankin Score for First Stroke of Any Type*
Rankin Score for First Stroke of Any Type*
160
140
120
100
80
60
40
20
0
Rankin 6 Rankin 5 Rankin 4 Rankin 3 Rankin 2 Rankin 1 Rankin 0 Rankin 6 Rankin 5 Rankin 4 Rankin 3 Rankin 2 Rankin 1 Rankin 0
Rankin 6 Rankin 5 Rankin 4 Rankin 3 Rankin 2 Rankin 1 Rankin 0
Modiﬁed Rankin Score (MRS) by occurrence of ﬁrst ischemic stroke (A) and occurrence of stroke at any time (B). Distribution of MRS for ﬁrst ischemic stroke (C) and for
stroke of any type (D).
Bonaca et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
Vorapaxar and New Stroke D E C E M B E R 9 , 2 0 1 4 : 2 3 1 8 – 2 6
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6 months after the event (11). Every year, 15 million
people worldwide experience a stroke (16), with the
majority being ischemic strokes (83%) (11). Although
the strongest predictor of ischemic stroke is prior
stroke, the majority of strokes each year occur in
patients with no history of prior stroke (77%)
because of the prevalence of other risk factors, such
as established atherosclerotic vascular disease (11). It
is recognized that patients with coronary artery
disease and PAD are at a heightened risk of a ﬁrst
stroke, and account for a signiﬁcant proportion
of patients presenting each year with a new
stroke (11,17).The accumulated evidence regarding antiplatelet
therapy to reduce the risk of stroke suggested a
complicated balance between its potential beneﬁts
for primary stroke prevention and its potential for
harm because of excess bleeding with high-intensity
regimens for secondary stroke prevention (4,7,18).
Meta-analyses by the Antithrombotic Trialists’
Collaboration showed a >20% reduction in stroke in
high-risk patients with antiplatelet monotherapy,
supporting this strategy for both primary and sec-
ondary stroke prevention (18,19). The efﬁcacy
of monotherapy with clopidogrel compared with
aspirin was investigated in the CAPRIE (Clopidogrel
Versus Aspirin in Patients at Risk of Ischaemic
FIGURE 6 Effect of Vorapaxar on Stroke Subtype Stratiﬁed by
Background Thienopyridine Therapy
All Ischemic Stroke
Ischemic Stroke with Hemorrhagic Conversion
Ischemic Stroke without Hemorrhagic Conversion
Favors Vorapaxar Favors Placebo
Hazard 
Ratio p-value
0.002 
0.29 
 0.99 
0.016 
0.008 
 0.018
0.057
0.018
0.54
0.57
0.65
0.70
0.59
0.56
1.00
0.60
p-interaction
0.75
0.56
0.91
0.79
All Stroke 
+ thienopyridine
– thienopyridine
+ thienopyridine
– thienopyridine
+ thienopyridine
– thienopyridine
+ thienopyridine
– thienopyridine
0.1 1.0 10
This ﬁgure shows the hazard of each stroke type with vorapaxar stratiﬁed by
background thienopyridine therapy.
J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4 Bonaca et al.
D E C E M B E R 9 , 2 0 1 4 : 2 3 1 8 – 2 6 Vorapaxar and New Stroke
2325Events) trial, which showed a numeric, but not sta-
tistically signiﬁcant, reduction in ischemic stroke
with clopidogrel, primarily in those patients who
qualiﬁed for the trial with stroke, rather than with
MI or PAD (20). Although DAPT with aspirin and
clopidogrel appeared potentially effective for the
reduction of all stroke and ischemic stroke in a post-
hoc analysis of the CHARISMA (Clopidogrel for High
Atherothrombotic Risk, Ischemic Stabilization, Man-
agement, and Avoidance) trial, in several large
dedicated trials of long-term secondary stroke pre-
vention, DAPT showed either lack of beneﬁt or
overall harm in multiple well-powered studies
(2–4,7,8).
This complicated balance may stem from the
heterogeneous etiologies of stroke events (e.g.,
cardioembolic, lacunar, hemorrhagic, or athero-
thrombotic) and whether all causes of ischemic
stroke are equally modiﬁable with antiplatelet
therapy. Indeed, outcomes with intensive anti-
platelet therapy appear to differ among subsets of
stroke patients, including harm in patients enrolled
in a trial with entry criteria of lacunar stroke, and
beneﬁt in a trial of patients enrolled with minor
acute ischemic stroke (8,21). It is plausible that
antiplatelet therapy would carry the greatest beneﬁt
in preventing atherothrombotic strokes, and those
at the greatest risk of this stroke subtype are
those with established atherosclerotic vascular
disease (15).
FINDINGS WITH VORAPAXAR. The main results from
the TRA 2P-TIMI 50 trial show a signiﬁcant reduction
in overall ischemic events with vorapaxar when
added to background antiplatelet therapy (2) (Central
Illustration). On the basis of these results, vorapaxar
was recommended for approval in patients with prior
MI or symptomatic PAD (9), but because of an excess
risk of intracranial hemorrhage, it should not be
administered to patients with a history of stroke or
TIA.
In the present analysis, we described the inci-
dence and subtypes of ﬁrst stroke in this popula-
tion, and demonstrated a signiﬁcant 33% reduction
in strokes of any kind and a 43% reduction in
ischemic stroke with vorapaxar. This beneﬁt of
vorapaxar was on the background of aspirin therapy,
and was observed whether or not a thienopyridine
was also used. The reduction in ischemic stroke was
also consistent at all levels of severity, as measured
by MRS. At the same time, vorapaxar increased the
risk of primary hemorrhagic stroke, but the fre-
quency was signiﬁcantly lower than the ischemic
stroke frequency, resulting in a signiﬁcant reductionin all strokes. In addition, we found an overall
decreased risk of ischemic stroke with hemorrhagic
conversion with vorapaxar compared with placebo,
which was due to a signiﬁcant reduction in ischemic
stroke. Importantly, we did not ﬁnd a signiﬁcant
increase in the risk of hemorrhagic conversion or
death in patients who had an ischemic stroke on
vorapaxar.
STUDY LIMITATIONS. In TRA 2P-TIMI 50, vorapaxar
was studied in addition to background antiplatelet
therapy and, therefore, the efﬁcacy and safety of
vorapaxar as monotherapy for stroke prevention
cannot be evaluated.
CONCLUSIONS
In stable patients with atherosclerotic vascular dis-
ease and no history of stroke or TIA, chronic therapy
with vorapaxar reduces the risk of ischemic stroke.
Although primary hemorrhagic stroke was increased
with vorapaxar, stroke of any kind was signiﬁcantly
reduced. This beneﬁt of vorapaxar is consistent when
given with aspirin or aspirin and a thienopyridine.
Patients who suffer a ﬁrst ischemic stroke on vor-
apaxar were not at a detectable increased risk of
subsequent intracranial hemorrhage or death when
vorapaxar was discontinued.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The risk of ﬁrst
ischemic stroke and subsequent outcomes in patients with
stable atherosclerotic vascular disease (history of myocardial
infarction or symptomatic peripheral artery disease) and no
history of stroke or transient ischemic attack treated with the
recently approved novel PAR-1 antagonist vorapaxar are un-
known. The objectives were to investigate both whether PAR-1
antagonism modiﬁes the risk of ischemic stroke and whether
patients who experience a ﬁrst ischemic stroke on vorapaxar are
at increased risk of hemorrhagic conversion or death. PAR-1
antagonism with vorapaxar signiﬁcantly reduced all strokes in
this population by 33% and ischemic stroke by 43%. No statis-
tically signiﬁcant increase in the risk of hemorrhagic conversion
or death was observed with vorapaxar when the agent was
stopped after a ﬁrst ischemic stroke.
TRANSLATIONAL OUTLOOK: PAR-1 antagonism reduces
the risk of stroke overall and ischemic stroke, and is not asso-
ciated with increased risk of hemorrhagic conversion or death
after stroke when therapy is stopped after ﬁrst ischemic stroke.
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